Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRoswell Park Cancer Institute

About this trial

This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and/or bone marrow transplant (hematopoietic cell transplantation \[HCT\]) or cellular therapy. The LIMS board delivers vibrations through the bones that may stimulate bone growth and may also increase muscle activity and strength and may also increase T-cell activation in patients planning to undergo cellular therapy. LIMS vibration therapy may stop or reverse BMD loss and/or improve the development of T-cells in the body in patients with hematologic malignancies who are undergoing or may plan to undergo HCT or cellular therapies.

Eligibility criteria

Qualifiers

COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)

COHORT I: Scheduled to undergo an autologous or allogeneic HCT

COHORT 1: >= 18 years of age

COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure

Disqualifiers

Any prior allogeneic HCT

Any prior autologous HCT for those patients who have a planned auto HCT

Pre-transplant weight >= 275 lbs. (max weight for the board)

Body mass index (BMI) < 18 kg/m²

Trial design

Treatments tested in this trial

  • Low Intensity Vibration Therapy
  • Dual X-ray Absorptiometry
  • Biospecimen Collection

Treatment groups

75 Participants
are divided into 2 treatment groups

Sponsors and collaborators